Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 214, Issue 1, Pages 3-16Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20161765
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [UM1 AI100663]
- Bill and Melinda Gates Foundation [OPP1033115]
- NIH [U19 AI109632]
- Robertson Foundation
- Clarin COFUND-Marie Curie program (PCTI-FICYT)
- Swedish Research Council
- Bill and Melinda Gates Foundation [OPP1033115] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
AIDS is a preventable disease. Nevertheless, according to UNAIDS, 2.1 million individuals were infected with HIV-1 in 2015 worldwide. An effective vaccine is highly desirable. Most vaccines in clinical use today prevent infection because they elicit antibodies that block pathogen entry. Consistent with this general rule, studies in experimental animals have shown that broadly neutralizing antibodies to HIV-1 can prevent infection, suggesting that a vaccine that elicits such antibodies would be protective. However, despite significant efforts over the last 30 years, attempts to elicit broadly HIV-1 neutralizing antibodies by vaccination failed until recent experiments in genetically engineered mice were finally successful. Here, we review the key breakthroughs and remaining obstacles to the development of active and passive HIV-1 vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available